Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in CTOR held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 9.2M | $5.7M | +64.5% | 9.883% | 0.17% |
| 2 | BANK OF AMERICA CORP /DE/ | 3.8M | $2.4M | +1792030.8% | 4.125% | 0.00% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 535K | $332K | — | 0.575% | 0.00% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 265K | $164K | +20.3% | 0.285% | 0.00% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 122K | $76K | — | 0.131% | 0.00% |
| 6 | IFP Advisors, Inc | 107K | $67K | +22.9% | 0.116% | 0.00% |
| 7 | BlackRock, Inc. | 47K | $29K | +112.4% | 0.051% | 0.00% |
| 8 | NORTHERN TRUST CORP | 46K | $28K | 0.0% | 0.049% | 0.00% |
| 9 | STATE STREET CORP | 43K | $27K | 0.0% | 0.046% | 0.00% |
| 10 | UBS Group AG | 37K | $23K | +71.6% | 0.040% | 0.00% |
| 11 | Arkadios Wealth Advisors | 12K | $7K | 0.0% | 0.013% | 0.00% |
| 12 | ADVISOR GROUP HOLDINGS, INC. | 10K | $6K | -11.4% | 0.011% | 0.00% |
| 13 | Caitong International Asset Management Co., Ltd | 1 | $1 | — | 0.000% | 0.00% |
| 14 | ROYAL BANK OF CANADA | 186 | $0 | +708.7% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in CTOR — a direct measure of their conviction.
Filings activity in CTOR during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new CTOR position in Q1 2026
Institutions that fully closed their CTOR position in Q1 2026
7 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 14 | 22% | 14.30% | +3.19 pp | $9M | +29% |
| Q4 2025 | 18 | +20% | 11.11% | 16.26 pp | $7M | 59% |
| Q3 2025 | 15 | +88% | 27.37% | +25.80 pp | $17M | +1648% |
| Q2 2025 | 8 | +0.0% | 1.57% | +1.39 pp | $1M | +788% |
| Q1 2025 | 8 | 33% | 0.18% | 0.07 pp | $0M | 29% |
| Q4 2024 | 12 | +71% | 0.25% | +0.20 pp | $0M | +380% |
| Q3 2024 | 7 | — | 0.05% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying CTOR stock.
Based on Q1 2026 13F filings, institutional ownership of Citius Oncology, Inc. stands at 14.3%, held across 14 reporting institutions.
ARMISTICE CAPITAL, LLC is the largest reported institutional holder of CTOR, with approximately 9,188,855 shares worth $0.01B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of CTOR.
Our composite Smart Money Score for CTOR is 37 out of 100 (Bearish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in CTOR during Q1 2026, while 7 fully exited. 4 added to existing positions and 6 trimmed.
CTOR institutional ownership rose by 3.19 percentage points quarter-over-quarter, with a net change of -4 holders.
The top 10 institutions account for 99.8% of all reported 13F value in CTOR, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Citius Oncology, Inc. (CTOR) Institutional Ownership